Effect of Rosiglitazone in type 2 diabetic nephropathy patients with C reactive protein

Objective:Observe the change of serum C-reactive protein(CRP) before and after rosiglitazone treatment of diabetic nephropathy,and investigate the relationship between inflammatory factors and diabetic nephropathy.Methods: 56 patients with type 2 diabetic nephropathy subjects were randomly divided into treatment groups of rosiglitazone(RSG group) and captopril treatment group(ACEI group),were applied RSG(4 mg/d) and captopril(25~50 mg/d) for 12 weeks,and observed CRP level changes before and after treatment.Results: 1.CRP is significantly different before and after treatment with rosiglitazone(6.81±1.73 mg/L vs 2.46±0.65 mg/L;P0.05).2.RSG group CRP(2.46±0.65 mg/L vs 3.96±1.00 mg/L;P0.05) and UAlb/Cre(28.22±1.65 μg/mg vs 37.83±2.73 μg/mg;P0.05) improved significantly than the control group.3.RSG group CRP and FPG,2hPG,fasting C peptide,HbA1C,UAlb/Cre were positively correlated(P0.01).Conclusion: Rosiglitazone treatment of early diabetic nephropathy in reducing inflammation and eventually to reduce urinary protein is superior than captopril possibly.